149 related articles for article (PubMed ID: 38411500)
1. Identification of
Jiang YJ; Xia Y; Hu YX; Han ZJ; Guo AY; Huang T
Thyroid; 2024 May; 34(5):583-597. PubMed ID: 38411500
[No Abstract] [Full Text] [Related]
2. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
[TBL] [Abstract][Full Text] [Related]
3. Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Associated Tumors-A Cohort Study.
Aswath K; Welch J; Gubbi S; Veeraraghavan P; Avadhanula S; Gara SK; Dikoglu E; Merino M; Raffeld M; Xi L; Kebebew E; Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne); 2021; 12():653401. PubMed ID: 34326811
[TBL] [Abstract][Full Text] [Related]
4. Identification of
Marques IJ; Gomes I; Pojo M; Pires C; Moura MM; Cabrera R; Santos C; van IJcken WFJ; Teixeira MR; Ramalho JS; Leite V; Cavaco BM
Thyroid; 2021 Sep; 31(9):1366-1375. PubMed ID: 33906393
[No Abstract] [Full Text] [Related]
5. Mutant MYO1F alters the mitochondrial network and induces tumor proliferation in thyroid cancer.
Diquigiovanni C; Bergamini C; Evangelisti C; Isidori F; Vettori A; Tiso N; Argenton F; Costanzini A; Iommarini L; Anbunathan H; Pagotto U; Repaci A; Babbi G; Casadio R; Lenaz G; Rhoden KJ; Porcelli AM; Fato R; Bowcock A; Seri M; Romeo G; Bonora E
Int J Cancer; 2018 Oct; 143(7):1706-1719. PubMed ID: 29672841
[TBL] [Abstract][Full Text] [Related]
6. Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.
Zhu J; Wu K; Lin Z; Bai S; Wu J; Li P; Xue H; Du J; Shen B; Wang H; Liu Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1015. PubMed ID: 31642198
[TBL] [Abstract][Full Text] [Related]
7. P21-activated kinase 4 involves TSH induced papillary thyroid cancer cell proliferation.
Xie X; Shi X; Guan H; Guo Q; Fan C; Dong W; Wang G; Li F; Shan Z; Cao L; Teng W
Oncotarget; 2017 Apr; 8(15):24882-24891. PubMed ID: 28178642
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
[TBL] [Abstract][Full Text] [Related]
9. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
[No Abstract] [Full Text] [Related]
10. Identification of a Novel Germline
Hu Y; Han Z; Guo H; Zhang N; Shen N; Jiang Y; Huang T
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38275415
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
12. Germ-line mutations in
Zhao Y; Yu T; Sun J; Wang F; Cheng C; He S; Chen L; Xie D; Fu L; Guan X; Yan A; Li Y; Miao G; Zhu X
Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34326253
[TBL] [Abstract][Full Text] [Related]
13. Investigating
Teixeira E; Fernandes C; Bungărdean M; Paula ADC; Lima RT; Batista R; Vinagre J; Sobrinho-Simões M; Máximo V; Soares P
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338801
[TBL] [Abstract][Full Text] [Related]
14.
Orois A; Gara SK; Mora M; Halperin I; Martínez S; Alfayate R; Kebebew E; Oriola J
Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31703244
[TBL] [Abstract][Full Text] [Related]
15. Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.
Yu Y; Dong L; Li D; Chuai S; Wu Z; Zheng X; Cheng Y; Han L; Yu J; Gao M
Sci Rep; 2015 Nov; 5():16129. PubMed ID: 26530882
[TBL] [Abstract][Full Text] [Related]
16. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of P21-activated kinase 4 is associated with poor prognosis in non-small cell lung cancer and promotes migration and invasion.
Cai S; Ye Z; Wang X; Pan Y; Weng Y; Lao S; Wei H; Li L
J Exp Clin Cancer Res; 2015 May; 34(1):48. PubMed ID: 25975262
[TBL] [Abstract][Full Text] [Related]
18. BROX haploinsufficiency in familial nonmedullary thyroid cancer.
Pasquali D; Torella A; Accardo G; Esposito D; Del Vecchio Blanco F; Salvatore D; Sabatino P; Pacini F; Barbato F; Castagna MG; Cantara S; Nigro V
J Endocrinol Invest; 2021 Jan; 44(1):165-171. PubMed ID: 32385852
[TBL] [Abstract][Full Text] [Related]
19. C14orf93 (RTFC) is identified as a novel susceptibility gene for familial nonmedullary thyroid cancer.
Liu C; Yu Y; Yin G; Zhang J; Wen W; Ruan X; Li D; Zhang S; Cai W; Gao M; Chen L
Biochem Biophys Res Commun; 2017 Jan; 482(4):590-596. PubMed ID: 27864143
[TBL] [Abstract][Full Text] [Related]
20. The role of p21-activated kinase 4 in the progression of oral squamous cell carcinoma by targeting PI3K-AKT signaling pathway.
Zhang L; Lin S; Zhang Z; Yan C; Liu F
Clin Transl Oncol; 2023 Mar; 25(3):739-747. PubMed ID: 36593383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
